Published in Obesity and Diabetes Week, June 12th, 2006
In this study, 30 subjects with type 2 diabetes, being treated with sulfonylureas and/or metformin, were expected to be enrolled. The primary objective was to explore the effect of daily doses 4.0 ml of AVR118 given subcutaneously on blood glucose, as compared to subjects not receiving AVR118. All 30 subjects have been enrolled.
Earlier this year, the company amended the protocol for this study to include an additional 12 subjects at a dose of 1.0 ml of AVR118 given subcutaneously daily for 15...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week